Drug Development Pipeline
Restore CFTR Function
Nesolicaftor is a new type of modulator called an amplifier. Amplifiers increase the amount of CFTR protein in the cell. This makes more CFTR protein available for other therapies, such correctors and potentiators, to work on.
Phase 2 studies have been conducted to test the safety and effectiveness of nesolicaftor alone and in combination with two other CFTR modulators, posenacaftor (PTI-801) and dirocaftor (PTI-808).
This program is sponsored by Proteostasis Therapeutics. It is being conducted through the Therapeutics Development Network.
Recent Nesolicaftor (PTI-428) Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More